Literature DB >> 20188173

Physiological cellular reprogramming and cancer.

Fernando Abollo-Jiménez1, Rafael Jiménez, Cesar Cobaleda.   

Abstract

The traditional approaches to cancer research and therapy have been primarily focused in the aspect of aberrant, uncontrolled, proliferation. Although this is clearly a very important issue, however, the emphasis on this characteristic has led to a relative neglect of an essential aspect of cancer biology: the alteration of normal differentiation processes. The oncogenic alterations that arise in an otherwise healthy cell lead to a whole reprogramming of the normal cellular fate and open a new pathologic developmental program. In this way cancer, reprogramming and cellular plasticity are tightly intertwined, since only some cells posses the necessary plasticity so as to allow the tumoral reprogramming to take place, and only some oncogenes have, in the right cellular context, the required tumoral reprogramming capacity. Research in the field of induced pluripotency is shedding a new light on the molecular mechanisms of tumor initiation and differentiation. In this review we discuss the latest findings in the area of cellular reprogramming and their implications from the point of view of tumor biology.

Entities:  

Mesh:

Year:  2010        PMID: 20188173     DOI: 10.1016/j.semcancer.2010.02.002

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  19 in total

Review 1.  Autophagy in stem and progenitor cells.

Authors:  Carlo Rodolfo; Sabrina Di Bartolomeo; Francesco Cecconi
Journal:  Cell Mol Life Sci       Date:  2015-10-26       Impact factor: 9.261

2.  Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes.

Authors:  Javier A Menendez; Tomás Alarcón; Bruna Corominas-Faja; Elisabet Cuyàs; Eugeni López-Bonet; Angel G Martin; Luciano Vellon
Journal:  Cell Cycle       Date:  2014-01-09       Impact factor: 4.534

3.  Multilineage-differentiating stress-enduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts.

Authors:  Shohei Wakao; Masaaki Kitada; Yasumasa Kuroda; Taeko Shigemoto; Dai Matsuse; Hideo Akashi; Yukihiro Tanimura; Kenichiro Tsuchiyama; Tomohiko Kikuchi; Makoto Goda; Tatsutoshi Nakahata; Yoshinori Fujiyoshi; Mari Dezawa
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-31       Impact factor: 11.205

Review 4.  Autophagy and cell reprogramming.

Authors:  Shuo Wang; Pengyan Xia; Markus Rehm; Zusen Fan
Journal:  Cell Mol Life Sci       Date:  2015-01-09       Impact factor: 9.261

Review 5.  Acute lymphoblastic leukemia and developmental biology: a crucial interrelationship.

Authors:  Elena Campos-Sanchez; Amparo Toboso-Navasa; Isabel Romero-Camarero; Marcos Barajas-Diego; Isidro Sanchez-García; César Cobaleda
Journal:  Cell Cycle       Date:  2011-10-15       Impact factor: 4.534

6.  The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells.

Authors:  Javier A Menendez; Jorge Joven; Sílvia Cufí; Bruna Corominas-Faja; Cristina Oliveras-Ferraros; Elisabet Cuyàs; Begoña Martin-Castillo; Eugeni López-Bonet; Tomás Alarcón; Alejandro Vazquez-Martin
Journal:  Cell Cycle       Date:  2013-04-02       Impact factor: 4.534

7.  Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Authors:  Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Silvia Cufí; José Manuel Moreno; Bruna Corominas-Faja; Ander Urruticoechea; Ángel G Martín; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

Review 8.  Adult cell plasticity in vivo: de-differentiation and transdifferentiation are back in style.

Authors:  Allyson J Merrell; Ben Z Stanger
Journal:  Nat Rev Mol Cell Biol       Date:  2016-03-16       Impact factor: 94.444

9.  Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by MafB.

Authors:  Carolina Vicente-Dueñas; Inés González-Herrero; María Begoña García Cenador; Francisco Javier García Criado; Isidro Sánchez-García
Journal:  Cell Cycle       Date:  2012-09-14       Impact factor: 4.534

10.  Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells.

Authors:  Alejandro Vazquez-Martin; Sílvia Cufí; Eugeni López-Bonet; Bruna Corominas-Faja; Elisabet Cuyàs; Luciano Vellon; Juan Manuel Iglesias; Olatz Leis; Angel G Martín; Javier A Menendez
Journal:  Cell Cycle       Date:  2013-10-04       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.